Svante & Meadow Lake Tribal Council Partnership Agrees to Sell Microsoft 626,000 Tonnes of Carbon Removal Credits
6.4.2026 18:00:00 EEST | Business Wire | Press release
Svante Technologies Inc. (Svante) and Meadow Lake Tribal Council (MLTC) announced today that North Star Carbon Solutions LP has entered into an offtake agreement with Microsoft to deliver 626,000 tonnes of durable carbon dioxide removal (CDR) credits to be delivered over 15 years from the North Star bioenergy with carbon capture and storage (BECCS) project in Saskatchewan, Canada. The project is being developed through a partnership between MLTC and Svante and will be co-located at the MLTC Bioenergy Centre in Meadow Lake.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260406630377/en/
As part of the project, a new carbon capture plant will be established at the MLTC Bioenergy Centre, a renewable power generation facility supplied by sustainable waste biomass from the adjacent sawmill owned by MLTC and other local forest product mills. The new plant will be owned by North Star Carbon Solutions LP, a partnership between MLTC and Svante’s recently acquired subsidiary, Carbon Alpha Corp. At capacity, the carbon capture plant will generate up to 90,000 tonnes of CDR credits per year and deliver CDR credits to Microsoft over a 15-year period. Captured CO2 will be safely transported and permanently stored at a geologic storage site owned and operated by North Star, providing a fully integrated system for carbon removal from source to sink.
The CDR credits delivered under the agreement are expected to be independently verified and issued in accordance with applicable carbon removal crediting standards and robust monitoring, reporting, and verification (MRV) practices. The North Star project plans to use waste biomass and to monitor CO2 capture, transport, and permanent geologic storage to support long-term durability.
Svante will provide all funding required until the decision is made to start construction. Commercial operation is planned for early 2029.
Scott Gardner, President of Svante Development Inc. said, “We are excited about this landmark agreement for BECCS in Canada, which is the result of Microsoft’s leadership in carbon removal. Microsoft’s anchor offtake commitment sends a strong signal to the market about the quality of North Star’s CDRs and the readiness of the Canadian market to deliver such projects.”
“Meadow Lake Tribal Council welcomes Microsoft’s significant offtake commitment for the North Star project,” said Jeremy Norman, Tribal Chief, Meadow Lake Tribal Council. “As a Canadian Indigenous-owned BECCS project that is believed to be among the first of its kind, North Star reflects MLTC Nations’ long-standing commitment to land stewardship and sustainable forest management. The project demonstrates how Indigenous leadership and collaboration can advance climate solutions while supporting meaningful employment and economic opportunities for our member Nations and the surrounding community.”
“We’re pleased to work with North Star Carbon Solutions and Meadow Lake Tribal Council to help advance high-quality, durable carbon dioxide removal,” said Phillip Goodman, Director of Carbon Removal Portfolio, Microsoft. “To meet our climate goals, we need to help scale solutions that deliver durable storage and are backed by rigorous monitoring and verification. This agreement supports an Indigenous-led collaboration that enables the infrastructure needed to bring durable carbon removal online in Canada, thus creating a pathway for additional projects over time.”
North Star is expected to create approximately 50 local jobs during the development and construction phase, and up to 10 ongoing jobs once the facility is operating, creating valuable employment opportunities for the Meadow Lake community. In addition, the project will support the local economy by increasing demand for nearby businesses such as restaurants, hotels, and service providers.
About Meadow Lake Tribal Council (MLTC)
MLTC was formed in 1981 and represents nine First Nations located in Northwest Saskatchewan. MLTC invests in businesses to meaningfully participate in Saskatchewan's economy, supporting economic reconciliation in a rural and remote area of the province. 100% of the distributions flow to the nine First Nations, to foster local economic growth; enhance on-reserve education; healthcare; youth and elder programs; housing; and other community social and infrastructure needs.
About Svante
Svante is a fully integrated carbon management company headquartered in Vancouver, BC, Canada. The company manufactures nanoengineered solid sorbent filters and modular rotating contactor machines, licenses CO2 capture technologies and offers project development services and capital covering the entire carbon capture, removal, and storage value chain. Svante is on the 2025 Global Cleantech 100 Hall of Fame and TIME & Statista’s list of Top Greentech Companies of 2025. For more information, visit www.svanteinc.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406630377/en/
Contacts
Media Contact:
Colleen Nitta
Director, Marketing & Communications
cnitta@svanteinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom